Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $30.00

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its price target hoisted by Mizuho from $24.00 to $30.00 in a report released on Monday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

AMLX has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. Citigroup upped their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Guggenheim boosted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Finally, Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $36.25.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $38.60 on Monday. The company has a market capitalization of $4.30 billion, a P/E ratio of -26.99 and a beta of -0.21. Amylyx Pharmaceuticals has a one year low of $7.82 and a one year high of $39.07. The business’s 50 day simple moving average is $19.38 and its 200-day simple moving average is $16.35.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the sale, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Millennium Management LLC raised its stake in shares of Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after buying an additional 2,487,617 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Amylyx Pharmaceuticals by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock valued at $7,090,000 after acquiring an additional 143,065 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Amylyx Pharmaceuticals by 62.7% in the second quarter. JPMorgan Chase & Co. now owns 87,989 shares of the company’s stock valued at $564,000 after acquiring an additional 33,920 shares during the last quarter. Legal & General Group Plc acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth $47,000. Finally, Rhumbline Advisers acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth $645,000. Institutional investors own 95.84% of the company’s stock.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Phase 3 success strengthens the product outlook. Avexitide met both the primary and secondary endpoints in the LUCIDITY trial, reducing hypoglycemic events by 55% in patients with PBH. The results provide Amylyx with a potentially important late-stage asset and support plans to submit an FDA application by the end of 2026. Reuters report on the avexitide trial
• Positive Sentiment: Analysts raised targets and ratings. Guggenheim lifted its target to $55 and assigned a “buy” rating; Robert W. Baird raised its target to $52 with an “outperform” rating; and H.C. Wainwright increased its target to $55 while maintaining a “buy” rating. Wolfe Research also upgraded the shares to “strong buy.” Benzinga analyst-rating updates
• Positive Sentiment: Investors are pricing in commercialization potential. Coverage characterized the trial as a major catalyst that could move avexitide closer to regulatory review and eventual commercialization, helping explain the unusually high trading activity and fresh stock high. Zacks analysis of Amylyx’s Phase 3 win
• Neutral Sentiment: Important milestones remain ahead. The results are topline data, so additional analysis, regulatory discussions, a formal FDA filing, and approval are still required. Commentary also cautioned that the sharp rally may have moved ahead of near-term fundamentals, increasing volatility and profit-taking risk. Invezz analysis of AMLX risks

Amylyx Pharmaceuticals Company Profile

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs.